In 2023, there were **** deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost ** deaths per 100,000 people in the early 2000s, and about ** deaths in 1980. Prevalence of diabetes In 2022, around *** percent of the adult population in the U.S. had diabetes. In total, around ** million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

Diabetes continues to be a significant global health concern, with the Western Pacific region reporting the highest number of diabetes-related deaths in 2024, with around 1.2 million. This stark figure underscores the urgent need for improved diabetes prevention and management strategies worldwide. North America and the Caribbean followed with an estimated 526,000 deaths, while Africa is had the lowest number at 216,000. Regional disparities and global impact The prevalence of diabetes varies significantly across regions, reflecting differences in healthcare systems, lifestyle factors, and genetic predispositions. In the United States, the death rate from diabetes mellitus was 22.4 per 100,000 people in 2023, with 8.4 percent of the adult population living with the condition. Canada has seen a slight decrease in its diabetes-related death rate, falling from 21.8 per 100,000 in 2000 to 18.1 per 100,000 in 2023. These figures highlight the ongoing challenges in managing diabetes, even in countries with advanced healthcare systems. European landscape and global context Within Europe, Germany reported the highest number of diabetes-related deaths in 2024, with nearly 63,000 fatalities among adults aged 20 to 79 years. Italy followed closely with around 62,400 deaths. However, Czechia reported the highest mortality rates in Europe as of 2022, with 43.4 diabetes deaths per 100,000 population overall. On a global scale, diabetes remains a major health concern, with 19 percent of adults worldwide identifying it as one of the biggest health problems in their country.

AH Provisional Diabetes Death Counts for 2020

  Description

Provisional death counts of diabetes, coronavirus disease 2019 (COVID-19) and other select causes of death, by month, sex, and age.

  Dataset Details

Publisher: Centers for Disease Control and Prevention Temporal Coverage: 2020-01-01/2020-12-31 Last Modified: 2025-04-21 Contact: National Center for Health Statistics (cdcinfo@cdc.gov)

  Source

Original data can be found at:… See the full description on the dataset page: https://huggingface.co/datasets/HHS-Official/ah-provisional-diabetes-death-counts-for-2020.

From 2017 to March 2020, the prevalence of diabetes was highest among those with lower incomes, with around ** percent of those who earned *** percent or less of the federal poverty level suffering from diabetes. This statistic shows the prevalence of diabetes in the U.S. from 2017 to March 2020, by family income relative to the federal poverty level (FPL).

This forecast represents the disease prevalence of diabetes type 2 in the United States from 2007 to 2020. In 2020, the prevalence for type 2 diabetes will amount to **** percent among the adult population in the United States.

This forecast illustrates the number of diabetes type 1 disease cases in the United States from 2007 to 2020. In 2020, some 500,000 adults of the U.S. population are expected to live with the type 1 diabetes.

From 2017 to March 2020, the prevalence of diabetes among Hispanics in the United States was **** percent. This statistic shows the prevalence of diabetes in the U.S. from 2017 to March 2020, by gender and race/ethnicity.

Yearly citation counts for the publication titled "Trends and Disparities in Diabetes Mellitus and Atrial fibrillation Related Mortality in the United States: 1999–2020".

BackgroundDiabetes is a growing health concern in the United States and especially New York City. New York City subsequently became an epicenter for the coronavirus pandemic in the Spring of 2020. Previous studies suggest that diabetes is a risk factor for adverse outcomes in COVID-19.ObjectiveTo investigate the association between diabetes and COVID-19 outcomes as well as assess other covariates that may impact health outcomes.DesignRetrospective cohort study of COVID-19 hospitalized patients from March to May, 2020.ParticipantsIn total, 1805 patients were tested for COVID-19 and 778 tested positive for COVID-19. Patients were categorized into 2 groups: diabetes (measured by an Hba1c >6.5 or had a history of diabetes) and those without diabetes.ResultsAfter controlling for other comorbidities, diabetes was associated with increased risk of mortality (aRR = 1.28, 95% CI 1.03–1.57, p = 0.0231) and discharge to tertiary care centers (aRR = 1.69, 95% CI 1.04–2.77, p = 0.036). compared to non-diabetes. Age and coronary artery disease (CAD) increased the risk of mortality among diabetic patients compared to patients with diabetes alone without CAD or advanced age. The diabetes cohort had more patients with resolving acute respiratory failure (62.2%), acute kidney injury secondary to COVID-19 (49.0%) and sepsis secondary to COVID-19 (30.1%).ConclusionThis investigation found that COVID-19 patients with diabetes had increased mortality, multiple complications at discharge, and increased rates of admission to a tertiary care center than those without diabetes suggesting a more severe and complicated disease course that required additional services at time of discharge.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This forecast illustrates the total medical costs due to type 2 diabetes in the United States from 2007 to 2020. In 2020, total medical costs for type 2 diabetes among adults in the United States will amount to approximately 363 billion U.S. dollars.

Cover image reference

Provisional counts of deaths by the week the deaths occurred, by state of occurrence, and by select underlying causes of death for 2020-2022. The dataset also includes weekly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

NOTE: death counts are presented with a one week lag.

This dataset to be updated weekly with the notebook run. The coverage period is between 2020-2022. This can used in conjunction with other datasets to plot the bigger picture. ex. 2014-2018

The dataset highlights select causes of death. Some prominent causes are not listed in specifics.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031. North America held the major market share of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031. Europe accounted for a share of over 30% of the global revenue with a market size of USD XX million. Asia Pacific held the market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031. Latin America market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031. Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031. The Injection segment held the highest Specific Antiviral Drugs for COVID-19 market revenue share in 2024. Market Dynamics of Specific Antiviral Drugs for COVID-19 Market Key Drivers for Specific Antiviral Drugs for COVID-19 Market Urgent need for effective treatments to Increase the Demand Globally The emergence of the COVID-19 pandemic has underscored an urgent necessity for efficacious treatments. In the United States, mortality rates surged by 19% from 2019 to 2020 following the pandemic's onset in March 2020 — marking the most significant spike in deaths in a century. This uptick translated to a staggering 19% rise (535,191) in deaths, from 2,854,838 to 3,390,029. With the virus persisting globally, there exists a critical market demand for pharmaceutical solutions capable of directly combating the virus, mitigating symptoms, and ameliorating disease severity. Rising prevalence of chronic diseases to Propel Market Growth Individuals with underlying chronic conditions, such as diabetes, hypertension, heart disease, or respiratory disorders, face an increased risk of severe complications if they contract COVID-19. According to the CDC, 90% of the nation’s $3.8 trillion per year healthcare costs are linked to individuals with chronic diseases and mental health conditions. In 2017, the total costs of diagnosed diabetes in the United States amounted to $327 billion, including $237 billion in direct medical costs and $90 billion in lost economic productivity. Cardiovascular disease, which accounts for one in three deaths in the United States, underscores the urgent need for effective treatments, including specific antiviral drugs, to mitigate the severity of COVID-19 symptoms and enhance outcomes for this vulnerable population. Restraint Factor for the Specific Antiviral Drugs for COVID-19 Market Stringent regulatory requirements and high cost of pharmaceutical development to Limit the Sales Stringent regulatory criteria and protracted approval processes may postpone the introduction of novel antiviral medications into the market. The thorough assessment of safety and efficacy data by regulatory bodies like the FDA can prolong the time required for market entry, influencing the accessibility of specific antiviral treatments. Moreover, the elevated expenses associated with pharmaceutical development, manufacturing, and distribution may lead to costly antiviral drugs, restricting access for populations in low-income countries or regions with insufficient healthcare infrastructure. Concerns regarding affordability could trigger pricing pressures and reimbursement obstacles, impacting the adoption and profitability of these medications. Impact of Covid-19 on the Specific Antiviral Drugs for COVID-19 Market The critical necessity for efficacious treatments against COVID-19 has sparked a heightened demand for targeted antiviral medications. Given the swift global dissemination of the virus and subsequent surges in infections, there is an urgent requirement for pharmaceutical solutions capable of directly combating the virus and mitigating associated symptoms. The pandemic has catalyzed unparalleled levels of investment and cooperation in research and development endeavors focused on discovering effective antiviral treatments for COVID-19. Pharmaceutical firms, academic entities, and governments across the globe have pri...

Overview

The Global Women’s Health Market is expected to reach US$ 66 Billion by 2033, rising from US$ 41.3 Billion in 2023, according to industry estimates. The market is projected to grow at a CAGR of 4.8% from 2024 to 2033. Growth is driven by shifts in population demographics and the rising focus on preventive care. According to United Nations projections, the population aged 65 years and older is likely to reach 2.2 billion by the late 2070s. This leads to a higher need for bone health, cardiometabolic services, cancer screening, and menopause care.

Noncommunicable diseases are placing a major burden on health systems. WHO reports confirm that NCDs caused 43 million deaths in 2021, which accounted for three quarters of all non-pandemic deaths. Notably, 18 million deaths occurred before age 70. The dominance of heart disease, diabetes, respiratory illnesses, and cancer strengthens demand for integrated primary and specialized care designed specifically for women. These conditions emphasize prevention, early diagnosis, and long-term disease management solutions.

Maternal and reproductive health needs are also significant. Study by UN agencies shows 287,000 maternal deaths in 2020, with limited progress since 2016. This situation supports investment in trained workforce, emergency obstetric care, and improved supply chains. Moreover, WHO indicates that among 1.9 billion women of reproductive age in 2021, 1.1 billion required family planning. 874 million used modern contraception, while 164 million still had unmet needs. For instance, UN DESA notes the rise in unmet need from 147 million in 1990 to current levels, signaling strong demand for accessible services.

Infertility care is advancing rapidly. WHO estimates note that 17.5% of adults, or one in six individuals, experience infertility. Similar prevalence is seen across all income regions. This trend expands opportunities in fertility diagnostics, assisted reproductive technologies, and supportive financing models. Preventive services are also expanding. WHO and UNICEF data confirm that adolescent girls receiving at least one HPV vaccine dose grew from 20% in 2022 to 27% in 2023. WHO’s 2025 update indicates 31% global first-dose coverage, strengthening screening and treatment service demand.

Cancer and mental health represent long-term growth areas. According to IARC, breast cancer remains the world’s most commonly diagnosed cancer, supporting continued investments in imaging, pathology, and survivorship care. WHO highlights that depression is 1.5 times more common in women, and more than 10% of pregnant women and 13% after childbirth experience mental disorders. Policy support is increasing as well. For example, ILO/World Bank data show 48.7% female labor force participation in 2023, encouraging workplace benefits. National strategies, such as England’s Women’s Health Strategy, further enhance attention to midlife health and menopause services.

From 2017 to March 2020, the prevalence of diabetes among adult men aged 60 years and older in the United States was around 36 percent. This statistic shows the prevalence of diabetes in the U.S. from 2017 to March 2020, by age and gender.

It was estimated that around 30 percent of those aged 80 years and older who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease. Deaths due to COVID-19 are much higher among those with underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

This forecast illustrates the total diabetes costs for adults in the United States between 2007 and 2020, sorted by type of diabetes. The total costs, including various types of diabetes, will amount to 3,351 billion U.S. dollars during the period 2011-2020.

This statistic depicts the rate of hospital readmissions in the United States for patients diagnosed with type 2 diabetes between 2020-2022, by therapy type. During these years, around ** percent of those diagnosed with diabetes were readmitted within ***** days for ***** non-insulin products.

It was estimated that around 20 percent of those with underlying health conditions who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease, compared to just 2 percent of COVID-patients without underlying health conditions. Underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes greatly increase the chance of death due to COVID-19. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 with and without underlying health conditions who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.